The use of oral progestin, despite requiring longer treatment time, is effective in relation to the gonadotropin-releasing hormone antagonist protocol and offers greater comfort at a lower cost in progesterone receptor negative breast cancer patients undergoing cancer fertility preservation. This evidence concerns the gene PGR and breast cancer.